MedTrace Logo

Study of Roxadustat for Reducing the Incidence of Acute Kidney Injury After Coronary Artery Bypass Grafting

NCT05010460 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 98

Last updated 2025-12-09

No results posted yet for this study

Summary

Acute kidney injury is a frequent complication after coronary artery bypass grafting (CABG). Roxadustat is a prolyl hydroxylase inhibitor (PHI) which can stabilize hypoxia-inducible factor (HIF) and improve the hypoxic tolerance of tissues. Roxadustat has shown effect in reducing acute kidney injury in animal studies.

This study aims to evaluate the efficacy of administration of Roxadustat before surgery in the prevention of acute kidney injury after CABG.

Conditions

  • Coronary Artery Bypass

Interventions

DRUG

Roxadustat

orally 100mg every other day for 5-8 days prior to CABG

DRUG

Placebo

orally 100mg every other day for 5-8 days prior to CABG

Sponsors & Collaborators

  • Beijing Hospital

    collaborator OTHER_GOV

  • Peking Union Medical College Hospital

    lead OTHER

Principal Investigators

  • Yan Qin, Doctor · Peking Union Medical College Hospital

  • Qi Miao, Doctor · Peking Union Medical College Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-30
Primary Completion
2025-05-20
Completion
2025-05-20

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05010460 on ClinicalTrials.gov